A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Acute myeloid leukemia is a type of cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer develops from myeloid blasts cells that would ...

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic stem ...

However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.